EUVIMEDEUVIMED entdecken
Crossref

Real-life experience and direct treatment costs in treatment of neovascular age-related macular degeneration

Betul Akbulut Yagci, Mahmut Kaya, Nilufer Kocak, Taylan Ozturk, Suleyman Kaynak

Annals of Clinical and Analytical Medicine · 01.03.2026 · 17 (3) · 196-202

DOI: 10.4328/acam.22693 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Analytical Medicine, erschienen am 01.03.2026. Verfasst von Betul Akbulut Yagci und 4 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To analyze the real-life long-term outcomes of anti-vascular endothelial growth factor (anti-VEGF) agents (ranibizumab, aflibercept) for the treatment of neovascular age-related macular degeneration (nAMD) and the cost-effectiveness of anti-VEGF agents.

Methods

This is a retrospective comparative study of treatment-naïve patients who received intravitreal ranibizumab or aflibercept administration for nAMD for at least 36 months on pro re nata (PRN) regimen after 3-monthly loading injections. The study included a total of 369 eyes of 289 patients treated with only ranibizumab (n = 178 eyes), only aflibercept (n = 137 eyes), and switching from ranibizumab to aflibercept (n = 54 eyes) between 2010 and 2020. According to treatment outcomes, the visual acuity (VA) changes from baseline, the total number of injections, and the cost-effectiveness of the drugs were analyzed.

Results

VA changes from baseline (decimal to Snellen Chart) were + 0.09 for ranibizumab, +0.05 for aflibercept, and +0.06 for the switch group at 12-months (p=0.66). Final VA changes also were + 0.04 for ranibizumab, no change for aflibercept, and -0.04 for the switch group (p=0.76). The mean (± SD) number of injections was 6,00 (±2.76) for ranibizumab, 6,58 (±3.12) for aflibercept, and 10.18 (±3.78) for switch eyes in the 36-month follow-up period (p=0.002). We found that ranibizumab is a cost-effective treatment for AMD over aflibercept for years 1-3.

Conclusion

Ranibizumab and aflibercept are similarly effective and safe treatments for nAMD. Ranibizumab can be more cost-saving and cost-effective compared with aflibercept for the treatment of nAMD.

Zitieren

APA

Yagci, B. A., Kaya, M., Kocak, N., Ozturk, T., & Kaynak, S. (2026). Real-life experience and direct treatment costs in treatment of neovascular age-related macular degeneration. Annals of Clinical and Analytical Medicine, 17(3), 196-202. https://doi.org/10.4328/acam.22693

Vancouver

Yagci BA, Kaya M, Kocak N, Ozturk T, Kaynak S. Real-life experience and direct treatment costs in treatment of neovascular age-related macular degeneration. Annals of Clinical and Analytical Medicine. 2026;17(3):196-202. doi:10.4328/acam.22693

BibTeX
@article{Yagci2026,
  author = {Yagci, Betul Akbulut and Kaya, Mahmut and Kocak, Nilufer and Ozturk, Taylan and Kaynak, Suleyman},
  title = {Real-life experience and direct treatment costs in treatment of neovascular age-related macular degeneration},
  journal = {Annals of Clinical and Analytical Medicine},
  year = {2026},
  volume = {17},
  number = {3},
  pages = {196--202},
  doi = {10.4328/acam.22693}
}
Kostenlos starten →